Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUMA study of pembrolizumab for locally advanced unresectable dMMR colorectal cancer
NL-OMON58701Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in colorectal cancer (CRC), colon adenocarcinoma and rectal adenocarcinoma, sponsored by Netherlands Cancer Institute. Started Dec 2022; status: active, not recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)colon adenocarcinomarectal adenocarcinoma
Beyond the preview
Go deeper on NL-OMON58701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58701.